Oncozenge AB (ONCOZ) - Total Assets
Based on the latest financial reports, Oncozenge AB (ONCOZ) holds total assets worth Skr19.84 Million SEK (≈ $2.13 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Oncozenge AB's book value for net asset value and shareholders' equity analysis.
Oncozenge AB - Total Assets Trend (2020–2024)
This chart illustrates how Oncozenge AB's total assets have evolved over time, based on quarterly financial data.
Oncozenge AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Oncozenge AB's total assets of Skr19.84 Million consist of 40.1% current assets and 59.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 33.8% |
| Accounts Receivable | Skr721.00K | 6.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr6.85 Million | 59.9% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Oncozenge AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ONCOZ stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncozenge AB's current assets represent 40.1% of total assets in 2024, a decrease from 40.5% in 2020.
- Cash Position: Cash and equivalents constituted 33.8% of total assets in 2024, up from 26.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 59.0% of total assets, an increase from 57.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 59.9% of total assets.
Oncozenge AB Competitors by Total Assets
Key competitors of Oncozenge AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Oncozenge AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.28 | 5.67 | 5.59 |
| Quick Ratio | 4.28 | 5.67 | 6.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr9.95 Million | Skr5.60 Million | Skr58.99 Million |
Oncozenge AB - Advanced Valuation Insights
This section examines the relationship between Oncozenge AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.77 |
| Latest Market Cap to Assets Ratio | 0.79 |
| Asset Growth Rate (YoY) | -43.8% |
| Total Assets | Skr11.43 Million |
| Market Capitalization | $9.07 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oncozenge AB's assets below their book value (0.79x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oncozenge AB's assets decreased by 43.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oncozenge AB (2020–2024)
The table below shows the annual total assets of Oncozenge AB from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr11.43 Million ≈ $1.23 Million |
-43.79% |
| 2023-12-31 | Skr20.34 Million ≈ $2.19 Million |
-44.87% |
| 2022-12-31 | Skr36.89 Million ≈ $3.97 Million |
-56.71% |
| 2021-12-31 | Skr85.23 Million ≈ $9.17 Million |
+122.55% |
| 2020-12-31 | Skr38.30 Million ≈ $4.12 Million |
-- |
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.